Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis

BMC Pulmonary Medicine

Table 3 Antibiotic susceptibility and virulence factors of S. pyogenes sputum isolates from adult cystic fibrosis patients

Patient	Iso-late	Antibiotic susceptibility						Virulence Factor Production^b
Patient	Iso-late	PEN	LVX	CAZ^a (mm)	CRO	CLI	AZM	Protease	Elastase	H₂O₂	DNAse	Chondroitin Sulfatase	AI-2
1	1	S	S	38	S	S	S	P	N	N	P	N	N
2	2	S	-	-	-	S	-	-	-	-	-	-	-
3	3	S	-	-	-	-	-	-	-	-	-	-	-
4	4	S	S	37	S	S	S	N	N	N	P	N	P
5	5	S	S	33	S	S	S	P	N	N	P	N	P
6	6	S	-	-	-	-	-	-	-	-	-	-	-
6	7	S	-	-	-	-	-	-	-	-	-	-	-
6	8	S	-	-	-	-	-	-	-	-	-	-	-
7	9	S	S	25	S	S	S	N	N	N	P	N	P
8	10	S	S	30	S	S	R	N	N	N	P	N	P
9	11	S	S	34	S	S	S	N	N	N	P	N	P
10	12	S	S	34	S	S	S	N	N	N	P	N	P
11	13	S	S	40	S	S	S	N	N	N	P	N	P
12	14	S	-	-	-	S	-	-	-	-	-	-	-
13	15	S	S	33	S	S	S	N	N	N	N	N	P
14	16	S	-	-	-	-	-	-	-	-	-	-	-
15	17	S	-	-	-	-	-	-	-	-	-	-	-
15	18	S	-	-	-	-	-	-	-	-	-	-	-
15	19	S	S	35	S	S	S	N	N	N	P	N	P
15	20	S	S	38	S	S	S	N	N	N	P	N	P
ATCC	19615	S	S	31	S	S	S	P	N	N	P	N	P

PEN Penicillin susceptibility
LVX Levofloxacin susceptibility
CAZ Ceftazidime susceptibility
CRO Ceftriaxone susceptibility
CLI Clindamycin susceptibility
AZM Azithromycin susceptibility
(-) Indicates frozen isolate could not be successfully recovered.
S Sensitive, I Intermediate, R=Resistant
^a = CLSI breakpoints do not exist for ceftazidime. Results reported as Kirby-Bauer zone sizes.
^b Production of virulence factors reported as strains producing those factors; P positive (Strains produced this virulence factor), or N=negative

ISSN: 1471-2466